ONCS · Oncosec Medical Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $25.82M | $34.10M | $25.10M | $18.45M | $17.42M | $11.95M |
| SG&A | $11.19M | $14.28M | $18.31M | $11.97M | $18.69M | $9.50M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $257.3K | $236.9K | $216.6K | $243.7K | $334.5K | $380.0K |
| Operating Income | ($37.01M) | ($48.38M) | ($43.41M) | ($30.42M) | ($21.62M) | ($26.89M) |
| Interest Expense | $20.9K | $15.9K | $5.1K | $3.8K | - | - |
| Income Tax | ($3.33M) | ($2.41M) | ($872.6K) | $1.3K | $680 | $1.4K |
| Net Income | ($34.18M) | ($45.17M) | ($42.25M) | ($30.28M) | ($39.14M) | ($21.45M) |
| EPS - Basic | ($0.87) | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.30M | $45.95M | $20.35M | $25.15M | $3.80M | $11.44M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $15.23M | $49.18M | $22.82M | $28.51M | $28.62M | $12.51M |
| Total Assets | $21.88M | $56.28M | $29.90M | $29.89M | $30.25M | $15.23M |
| Current Liabilities | $6.63M | $7.96M | $9.68M | $4.98M | $5.85M | $3.40M |
| Long-term Debt | $936.6K | $1.23M | $1.45M | - | - | - |
| Total Liabilities | $15.76M | $18.20M | $16.03M | $5.61M | $7.32M | $4.54M |
| Stockholders' Equity | $6.12M | $38.08M | $13.87M | $24.28M | $22.92M | $10.70M |
| Retained Earnings | ($285.96M) | ($251.78M) | ($206.61M) | ($164.36M) | ($134.08M) | ($94.94M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($32.14M) | ($41.79M) | ($33.15M) | ($29.00M) | ($17.34M) | ($17.34M) |
| Investing Cash Flow | ($244.9K) | ($799.6K) | - | $23.20M | ($21.6K) | ($21.6K) |
| Financing Cash Flow | ($1.16M) | $68.21M | $28.40M | $27.20M | $64.0K | $64.0K |
| CapEx | $244.9K | $304.6K | - | $9.9K | $65.2K | $21.6K |
| Free Cash Flow | ($32.38M) | ($42.10M) | - | ($29.01M) | ($17.41M) | ($17.36M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.95 | 0.93 | - | 0.96 | 0.44 | 0.81 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -156.2% | -80.3% | -141.3% | -101.3% | -129.4% | -140.8% |
| Return on equity | -558.6% | -118.6% | -304.6% | -124.7% | -170.7% | -200.5% |
| Return on invested capital | -414.5% | -97.2% | -223.8% | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.30 | 6.18 | 2.36 | 5.73 | 4.89 | 3.68 |
| Quick ratio | 2.30 | 6.18 | 2.36 | 5.73 | 4.89 | 3.68 |
| Cash ratio | 1.85 | 5.77 | 2.10 | 5.05 | 0.65 | 3.37 |
| Leverage | ||||||
| Debt / Equity | 0.15 | 0.03 | 0.10 | - | - | - |
| Debt / Assets | 0.04 | 0.02 | 0.05 | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -1768.8x | -3051.0x | -8488.3x | -7993.9x | - | - |
| Equity multiplier | 3.58 | 1.48 | 2.16 | 1.23 | 1.32 | 1.42 |
| Liabilities / Assets | 0.72 | 0.32 | 0.54 | 0.19 | 0.24 | 0.30 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 23.5% | -11.5% | -42.7% | -40.7% | 19.6% | 0.0% |
| Net income growth (YoY) | 24.3% | -6.9% | -39.6% | 22.6% | -82.5% | 20.2% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 23.1% | - | - | -66.7% | -0.3% | 10.0% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -83.9% | 174.5% | -42.9% | 5.9% | 114.3% | -61.9% |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ONCOSEC MEDICAL Inc against the 5 most active filers in the same SIC group.